- Date 20 January 2016
- Documents : 4
- Economic analysis
- History
Listen
MEKINIST (trametinib), protein kinase inhibitor
ONCOLOGY - New indication
Opinions on drugs -
Posted on
Mar 18 2016
Reason for request
Inclusion
Moderate improvement as first-line treatment of unresectable or metastatic melanoma, in patients with a BRAF V600 mutation
- MEKINIST now has Marketing Authorisation in combination with dabrafenib, in the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.
- Combining MEKINIST with dabrafenib improves progression-free survival and overall survival in comparison with dabrafenib alone.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| moderate |
- |
Therapeutic use
|
- |
-
Economic analysis
English version
Contact Us
Évaluation des médicaments
